Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

    NEXT STORY
    AirLife Virginia Receives Industry-Leading Accreditation for Quality and Safety Standards
    PREV STORY
    Rising Demand for Cost-Efficient Solutions Set to Expand Global Smart Hospital Market: WiseGuyReports
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

    Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with ...

    author_avatar
    NASDAQ Market News

    Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial

    PENNVAX®-GP generated among highest levels of immune responses ever demonstrated in a human HIV ...

    author_avatar
    NASDAQ Market News

    Immunovaccine and UConn Health Extend Collaboration to Support Advancement of Patient-Specific Immunotherapies to the Clinic

    HALIFAX, Nova Scotia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the ...

    author_avatar
    NASDAQ Market News